Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron (REGN) reports initial data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory (R/R) multiple myeloma.

Regeneron Reports Initial Data for Multiple Myeloma Drug

ABIOMED

Align Technology

MarketAxess Holdings

Netflix

NVIDIA

TransDigm

Take-Two Interactive Software

Ulta Beauty

United Rentals

As 2019 comes to a close, a new decade will be upon us. The incredible bull market will also be in its eleventh year since the v-bottom marked in March of 2009.

10 Large Cap Stocks Up 1,000% to 4,000% Over the Last Decade

Canopy Growth

Esperion Therapeutics

Medicines

OrganiGram Holdings Inc.

Marijuana beverages, edibles, and vapes are finally available in Canada, but marijuana stocks still have big obstacles to overcome.

Can Cannabis 2.0 Kickstart Marijuana Stocks?

Regeneron (REGN) announces positive top-line data from a phase II study on rare blood disorder drug.

Regeneron Reports Positive Data on Rare Blood Disorder Drug

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?

Why Is Regeneron (REGN) Up 14% Since Last Earnings Report?

Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Piper Jaffray 31st Annual Healthcare Broker Conference Call (Transcript)

BioMarin Pharmaceutical

REGN vs. BMRN: Which Stock Is the Better Value Option?

REGN or BMRN: Which Is the Better Value Stock Right Now?

Regeneron Pharmaceuticals (NASDAQ:REGN) is a U.S.-based biotech company focused on manufacturing novel biologics.

Understanding Why Regeneron Pharmaceuticals’ Stock Has Gained 25% In 2 Months

Amgen

Novartis

Sanofi

Swiss drugmaker Novartis  is betting on heart drug prospect inclisiran in a $9.7 billion takeover of The Medicines Co  as it challenges cardiovascular medicines from Amgen Inc , Sanofi  and Regeneron Pharmaceuticals.

Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug maker

Regeneron Pharmaceuticals, Inc.'s (REGN) Management Presents at Jefferies London Healthcare Conference (Transcript)

Alexion Pharma

Incyte

Vertex Pharmaceuticals

We highlight a few principal players from the biotech sector, which are likely to witness a winning run in the near term.

4 Big Biotech Stocks Worth Considering Post Q3 Earnings

Brinker International

Fulgent Genetics

Hewlett Packard

Sonic Automotive

By following broker rating upgrades, an investor can easily find attractive stocks.

Buy These 5 Top-Ranked Stocks With Upgraded Broker Ratings.

Regeneron Rebounds Again: A Progress Report

AbbVie

Biogen

Innoviva

Mylan

Theravance Biopharma

With biotech stocks back in favor, investors may selectively pick only those with a deep drug pipeline ahead.

7 Biotech Stocks to Buy With Plenty of Power in the Pipeline        

Kraft Heinz

Westinghouse Air Brake Technologies

Thursday's big stock charts detail the hopes for 3 stocks trying to recover from multi-year lows.
The post 3 Big Stock Charts for Thursday: Kraft Heinz, Wabtec, and Regeneron Pharmaceuticals appeared first on InvestorPlace.

3 Big Stock Charts for Thursday: Kraft Heinz, Wabtec, and Regeneron Pharmaceuticals

Regeneron Pharmaceuticals (REGN) earnings for the biotechnology company's third quarter of 2019 have REGN stock soaring on Tuesday.

Regeneron Pharmaceuticals Earnings: REGN Stock Rockets 7% on Q3 Beat

Regeneron: Onward And Upward

As Eylea and Dupixent go, so goes Regeneron.

Regeneron Pharmaceuticals Tops Q3 Estimates Thanks to Soaring Sales of 2 Drugs

Regeneron Pharmaceuticals, Inc. (REGN) CEO Len Schleifer on Q3 2019 Results - Earnings Call Transcript

Regeneron (REGN) beats on Q3 earnings and sales on the back of solid demand for ophthalmology drug, Eylea, and asthma drug, Dupixent.

Regeneron's (REGN) Q3 Earnings Beat on Dupixent Strength

Regeneron earnings and sales were well above Q3 estimates, while the biotech also announced a $1 billion stock buyback. Regeneron stock was quiet early.

Regeneron Earnings Crush Views; Biotech Plans $1 Billion Buyback

Allergan

Catalent

Jazz Pharmaceuticals

Let us take a look at five drug/biotech companies, which are supposed to release their quarterly results on Nov 5.

Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports third-quarter 2019 results.

Is a Beat in the Cards for Regeneron (REGN) Q3 Earnings?

Shares of Regeneron Pharmaceuticals slipped Thursday after Amgen said it will discontinue a costly version of its high cholesterol treatment, Repatha. Regeneron makes a rival medicine.

News for Regeneron Pharmaceuticals Stock (REGN)